WebbNeuroTheryX and Cyclica form a new joint venture, NineteenGale, to identify and develop novel cannabinoid-inspired drugs. Webb24 juni 2024 · Led by Drive Capital, the investment round includes Chiesi Farmaceutici, GreenSky Capital, and members of management. Proceeds will advance Cyclica’s AI-augmented, polypharmacology-enabled,...
NeuroTheryX Partners with Cyclica to Launch NineteenGale …
Webb19 mars 2024 · Based on the success of the initial collaboration, NeuroTheryX and Cyclica join forces to launch NineteenGale Therapeutics, a joint venture creating the next … WebbExplore NineteenGale Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here! Home. PRO Data. Investor Insights. Investors & VCs Raised. M&A Insights. IPO Insights. Lead Investors. Accelerators & Incubators. Companies. Corporate VCs. Clinical Insights. der idiot von dostojewski
CYCLICA Business Wire
Webb20 mars 2024 · Nineteengale Therapeutics is a new joint venture that was launched to fill a large void. Cyclica Inc., along with its partner, Neurotheryx Canada Ltd., both of Toronto, created Nineteengale to find and develop cannabinoid-inspired drugs for bipolar disorder, anxiety and pain management. WebbWith quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed … WebbIn this Dashboard we provide a bird’s eye view of the emerging field of pharmaceutical artificial intelligence -- from data mining and biology research to clinical trial management, regulatory filings and pharmacovigilance -- categorizing key players by the type of AI technology, business cases, R&D cases, and other important aspects reflecting … der baron projekt